Innovent - Eli Lilly's Sintilimab Combo Shows Sustained Survival Benefit In Lung Cancer Patients - Eli Lilly and Co (NYSE:LLY), Innovent Biologics (OTC:IVBIY), Innovent Biologics (OTC:IVBXF)

Innovent Biologics Inc IVBIY and Eli Lilly And Co LLY have announced new and updated data from the ORIENT-11 Phase 3 study of sintilimab as first-line treatment of nonsquamous non-small cell lung cancer (NSCLC).
The trial assessed sintilimab in combination with pemetrexed and platinum chemotherapy.
The findings were published in the Journal of Thoracic Oncology.
As of January 15, 2021, with a median follow-up of 22.9 months, the median overall survival (OS) of patients receiving the sintilimab combination was not yet reached.
The sintilimab combination demonstrated a sustainable OS benefit, and the median OS for those receiving the placebo combination was 16.8 months.
Biomarker analysis showed that high or medium immune cell infiltration was strongly associated with improved progression-free survival (PFS) in the sintilimab combination group.
In particular, high MHC class-II presentation pathway expression was significantly correlated with prolonged PFS and OS in the sintilimab combination group.
Price Action: LLY shares are down 0.53% at $262.85 on the last check Friday.

Innovent - Eli Lilly's Sintilimab Combo Shows Sustained Survival Benefit In Lung Cancer Patients